---
title: "TrialCalibre1: Agentic System for Trial Emulation, Benchmarking, and Calibration"
id: "medrxiv-9-trialcalibre1-an-agentic-system-for-trial-emulation-benchmarking-and-calibration"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-9-trialcalibre1-an-agentic-system-for-trial-emulation-benchmarking-and-calibration"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.13.26365421v1?rss=1"
published_at: "2026-10-14T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# TrialCalibre1: Agentic System for Trial Emulation, Benchmarking, and Calibration
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-9-trialcalibre1-an-agentic-system-for-trial-emulation-benchmarking-and-calibration
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.13.26365421v1?rss=1)
- **Published At:** 2026-10-14T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- TrialCalibre1 is an agentic system that links clinical evidence, study design, and executable analyses to support reference-trial replication and direct target-trial emulation. - The platform includes a BenchExCal workflow combining benchmarking, extension, and calibration sensitivity analysis to probe estimate robustness. - Investigators evaluated an ASCET-based benchmark and an extension comparing **clopidogrel** with **aspirin** in adults aged 81–90 using synthetic **PCORnet**-style claims data. - Two reviewers assessed benchmark extraction, protocol decisions, and implementation; initial automated checks were reconciled through discussion. - SQL implementation checks: reviewers rated 53/62 and 50/62 assessable SQL checks as met; R checks: both reviewers rated 12/13 assessable R checks as met. - A routing development set of ten questions produced 10/10 route matches and 7/7 applicable reference trial matches, per the authors. - The agent benchmark cohort included 6,069 patients; the extension cohort included 1,602 patients. - The extension produced a risk ratio of 0.848 (95% CI 0.569–1.184); calibrated sensitivity analysis yielded 1.274 (0.439–3.700). - Authors and reviewers noted important implementation limitations: dose proxies, unpopulated covariates, residual imbalance, deviations from implementation, and ignored cross-cohort covariance. - The human implementation was descriptive and not a same-data validation; the report makes protocols, code, and results available for inspection upon request.
## Clinical Analysis & Structured Key Points
TrialCalibre1: An Agentic System for Trial Emulation, Benchmarking, and Calibration | medRxiv Skip to main content TrialCalibre1: An Agentic System for Trial Emulation, Benchmarking, and Calibration Amir Habibdoust , Xing Song doi: https://doi.org/10.64898/2026.10.13.26365421 Amir Habibdoust University of Missouri-Columbia Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: ahb3b{at}missouri.edu Xing Song University of Missouri-Columbia Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Data/Code Preview PDF Abstract TrialCalibre1 is an agentic system that connects clinical evidence, study design, and executable analyses. It supports reference-trial replication, direct target-trial emulation, and BenchExCal, which combines benchmarking, extension, and cal ibration sensitivity analysis. We evaluated an ASCET-based benchmark and an extension comparing clopidogrel with aspirin among adults aged 81-90 years us ing synthetic PCORnet-style claims. Two reviewers assessed benchmark extrac tion, protocol decisions, and implementation. After discussion, 53/62 and 50/62 assessable SQL checks were rated met; both reviewers rated 12/13 assessable R checks met. Protocol and proxy disagreements remained. A separate ten-question routing development set yielded 10/10 route matches and 7/7 applicable reference trial matches. The agent benchmark and extension included 6,069 and 1,602 pa tients. The extension risk ratio was 0.848 (95% CI 0.569-1.184), with a calibrated sensitivity estimate of 1.274 (0.439-3.700). The human implementation provided descriptive comparisons, not same-data validation. Dose proxies, unpopulated co variates, residual imbalance, implementation deviations, and ignored cross-cohort covariance limited interpretation. This case demonstrates a connected workflow whose protocols, code, and results can be reviewed. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present study are available upon reasonable request to the authors Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted October 14, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following TrialCalibre1: An Agentic System for Trial Emulation, Benchmarking, and Calibration Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share TrialCalibre1: An Agentic System for Trial Emulation, Benchmarking, and Calibration Amir Habibdoust , Xing Song medRxiv 2026.10.13.26365421; doi: https://doi.org/10.64898/2026.10.13.26365421 Share This Article: Copy Citation Tools TrialCalibre1: An Agentic System for Trial Emulation, Benchmarking, and Calibration Amir Habibdoust , Xing Song medRxiv 2026.10.13.26365421; doi: https://doi.org/10.64898/2026.10.13.26365421 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (628) Allergy and Immunology (914) Anesthesia (343) Cardiovascular Medicine (4923) Dentistry and Oral Medicine (488) Dermatology (421) Emergency Medicine (667) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1655) Epidemiology (16115) Forensic Medicine (35) Gastroenterology (1228) Genetic and Genomic Medicine (7167) Geriatric Medicine (740) Health Economics (1079) Health Informatics (5180) Health Policy (1452) Health Systems and Quality Improvement (1807) Hematology (595) HIV/AIDS (1362) Infectious Diseases (except HIV/AIDS) (16396) Intensive Care and Critical Care Medicine (1187) Medical Education (684) Medical Ethics (156) Nephrology (733) Neurology (7435) Nursing (372) Nutrition (1110) Obstetrics and Gynecology (1274) Occupational and Environmental Health (1020) Oncology (3687) Ophthalmology (1077) Orthopedics (400) Otolaryngology (461) Pain Medicine (488) Palliative Medicine (142) Pathology (714) Pediatrics (1837) Pharmacology and Therapeutics (744) Primary Care Research (780) Psychiatry and Clinical Psychology (6032) Public and Global Health (9882) Radiology and Imaging (2479) Rehabilitation Medicine and Physical Therapy (1495) Respiratory Medicine (1258) Rheumatology (654) Sexual and Reproductive Health (791) Sports Medicine (591) Surgery (793) Toxicology (109) Transplantation (313) Urology (299)
## Related Clinical Research

- [Clopidogrel vs Prasugrel in Endovascular Treatment of Unruptured Intracranial Aneurysms: TriNetX P](https://medichelpline.com/clinical-feed/medrxiv-8-clinical-outcomes-after-clopidogrel-versus-prasugrel-use-in-endovascular.md)
- [Bupropion Hydrochloride for Improving Recovery in Acute Ischaemic Stroke: BASE Trial Protocol](https://medichelpline.com/clinical-feed/bmj-open-4-protocol-for-base-a-multicentre-double-blind-randomised-controlled-trial-of.md)
- [Cost-effectiveness of rivaroxaban plus aspirin in COMPASS: a Scandinavian lifetime analysis](https://medichelpline.com/clinical-feed/pubmed-42700109.md) (DOI: 10.1080/14017431.2026.2728343)
- [Linear micro-patterned drug-coated balloon reduces early neointimal growth in porcine coronary ISR](https://medichelpline.com/clinical-feed/plos-one-16-surface-micro-patterned-drug-coated-balloon-enhances-early-biological-efficacy.md)
- [Pulmonary artery growth after PDA stent versus modified Blalock–Taussig shunt in ductal-dependent](https://medichelpline.com/clinical-feed/plos-one-20-comparative-outcomes-of-pulmonary-artery-changes-in-ductal-patency-dependent.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.